clinical trial · NCT06880354
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China·phase1·recruiting·n = 37
Acute Myeloid LeukemiaCLL1 and CD38 Dual-Target CAR-T Cell Injection
brief summary
This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.
started
May 22, 2025
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Jun 3, 2025
detailed description
This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.
The main purpose of this study is to evaluate the safety of CLL1 and CD38 dual - target CAR - T cell injection in the treatment of r/r AML and the study contains two phases with the first phase adopting an ATD design and the second phase adopting a 3+3 design.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol